Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
DXOR23
|
|||
Drug Name |
225Ac-J591
|
|||
Synonyms |
CONV01-alpha
Click to Show/Hide
|
|||
Drug Type |
Antibody
|
|||
Indication | Prostate cancer [ICD-11: 2C82.0; ICD-9: 185] | Phase 1 | [1] | |
Company |
Convergent Therapeutics
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Glutamate carboxypeptidase II (GCPII) | Target Info | . | [2] |
KEGG Pathway | Alanine, aspartate and glutamate metabolism | |||
Metabolic pathways | ||||
Vitamin digestion and absorption | ||||
NetPath Pathway | TCR Signaling Pathway | |||
TNFalpha Signaling Pathway | ||||
Reactome | Amino acid synthesis and interconversion (transamination) | |||
WikiPathways | One Carbon Metabolism |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT03276572) Phase I Dose-Escalation Trial of 225Ac-J591 in Patients With Metastatic Castration-Resistant Prostate Cancer. U.S.National Institutes of Health. | |||
REF 2 | Novel agents and clinical trials in castration-resistant prostate cancer: latest updates from 2023 ASCO-GU Cancers Symposium. Exp Hematol Oncol. 2023 Aug 1;12(1):68. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.